

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

#### **Listing of Claims:**

Claim 1. (withdrawn) A method of inhibiting an LPS-dependent inflammatory processes in a patient infected with a bacterium comprising administering to said patient an amount of recombinant human uteroglobin sufficient to inhibit said inflammatory processes.\

Claim 2. (withdrawn) The method of claim 84 wherein said patient is diagnosed with septic shock.

Claim 3. (withdrawn) The method of claim 84 wherein said patient is diagnosed with pneumonia.

Claim 4. (withdrawn) The method of claim 84 wherein said patient is diagnosed with a condition selected from the group consisting of: peritonitis, colitis, inflammatory bowel disease, pancreatitis, nephritis, vasculitis, hepatitis, sinusitis, cystitis, periodontal disease, and myocarditis.

Claim 5. (withdrawn) The method of claim 84 wherein said patient is diagnosed with asthma.

Claim 6. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to inhibit LPS-dependent inflammatory processes in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 7. (currently amended) The composition of claim 6 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 8. (withdrawn) A method of decreasing TNF-alpha concentrations in vivo in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to decrease said TNF-alpha concentrations.

Claim 9. (withdrawn) The method of claim 8 wherein said patient is diagnosed with a bacterial infection.

Claim 10. (withdrawn) The method of claim 8 wherein said patient is diagnosed with inflammatory disease.

Claim 11. (withdrawn) The method of claim 8 wherein said patient is diagnosed with Crohn's disease.

Claim 12. (withdrawn) The method of claim 8 wherein said patient is diagnosed with a condition selected from the group consisting of: peritonitis, colitis, inflammatory bowel disease, pancreatitis, nephritis, vasculitis, hepatitis, sinusitis, cystitis, periodontal disease, and myocarditis.

Claim 13. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to decrease TNF-alpha concentrations and a pharmaceutically acceptable carrier or diluent.

Claim 14. (currently amended) The composition of claim 13 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 15. (withdrawn) A method of regulating the nitric oxide pathway for relaxing smooth muscle cells in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to regulate said nitric oxide pathway.

Claim 16. (withdrawn) The method of claim 15 wherein said patient is diagnosed with abnormal blood pressure.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 17. (withdrawn) The method of claim 15 wherein said patient is diagnosed with high blood pressure.

Claim 18. (withdrawn) The method of claim 15 wherein said patient is diagnosed with bronchoconstriction.

Claim 19. (withdrawn) The method of claim 15 wherein said patient is diagnosed with respiratory distress syndrome.

Claim 20. (withdrawn) The method of claim 15 wherein said patient is diagnosed with esophageal dysphagia.

Claim 21. (withdrawn) The method of claim 15 wherein said patient is diagnosed with ileus.

Claim 22. (withdrawn) The method of claim 15 wherein said patient is diagnosed with rectal prolapse.

Claim 23. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to regulate the nitric oxide pathway of a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 24. (currently amended) The composition of claim 23 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 25. (withdrawn) A method of regulating vascular permeability in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to regulate said vascular permeability.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 26. (withdrawn) The method of claim 25 wherein said patient is diagnosed with abnormal blood pressure.

Claim 27. (withdrawn) The method of claim 25 wherein said patient is diagnosed with high blood pressure.

Claim 28. (withdrawn) The method of claim 25 wherein said patient is diagnosed with primary pulmonary hypertension.

Claim 29. (withdrawn) The method of claim 25 wherein said patient is diagnosed with congestive heart failure.

Claim 30. (withdrawn) The method of claim 25 wherein said patient suffers from edema.

Claim 31. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to regulate vascular permeability of a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 32. (currently amended) The composition of claim 31 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 33. (withdrawn) A method of suppressing proliferation of CD71-positive cells in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to suppress proliferation of said cells.

Claim 34. (withdrawn) A method of claim 33 wherein said patient is diagnosed with a leukemia.

Claim 35. (withdrawn) A method of claim 33 wherein said patient is diagnosed with a lymphoma.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 36. (withdrawn) A method of claim 33 wherein said patient is diagnosed with an inflammatory disease.

Claim 37. (withdrawn) The method of claim 33 wherein said patient is diagnosed with an infectious disease.

Claim 38. (withdrawn) A method of claim 33 wherein said patient is diagnosed with a fibrotic disease.

Claim 39. (withdrawn) A method of claim 33 wherein said patient is diagnosed with an autoimmune disease.

Claim 40. (withdrawn) A method of claim 33 wherein said patient is diagnosed with cancer.

Claim 41. (withdrawn) A method of claim 33 wherein said cells are selected from the group consisting of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

Claim 42. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to suppress proliferation of CD71 positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 43. (currently amended) The composition of claim 42 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 44. (withdrawn) A method of suppressing proliferation of CD71-positive cells in vitro comprising exposing said CD71-positive cells to an amount of recombinant human uteroglobin sufficient to suppress proliferation of said cells in vitro.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 45. (withdrawn) The method of claim 44 wherein said CD71-positive cells are hematopoietic stem cells.

Claim 46. (withdrawn) The method of claim 44 wherein said hematopoietic stem cells are transplanted from a donor to a recipient in need of such cells.

Claim 47. (withdrawn) The method of claim 44 wherein said hematopoietic stem cells must be stored for a period of time prior to transplant.

Claim 48. (withdrawn) The method of claim 44 wherein said CD71-positive cells are lymphoid precursor cells.

Claim 49. (withdrawn) The method of claim 44 wherein said CD71-positive cells are myeloid precursor cells.

Claim 50. (withdrawn) The method of claim 44 wherein said cells are selected from the group consisting of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

Claim 51. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to suppress proliferation of CD71 positive cells in vitro.

Claim 52. (currently amended) The composition of claim 51 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 53. (withdrawn) A method of suppressing proliferation of CD71-positive cells in vitro comprising exposing said CD71-positive cells to an amount of recombinant human uteroglobin and an amount of fibronectin sufficient to suppress proliferation of said cells in vitro.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 54. (withdrawn) The method of claim 53 wherein said CD71-positive cells are hematopoietic stem cells.

Claim 55. (withdrawn) The method of claim 53 wherein said hematopoietic stem cells are transplanted from a donor to a recipient in need of such cells.

Claim 56. (withdrawn) The method of claim 53 wherein said hematopoietic stem cells must be stored for a period of time prior to transplant.

Claim 57. (withdrawn) The method of claim 53 wherein said CD71-positive cells are lymphoid precursor cells.

Claim 58. (withdrawn) The method of claim 53 wherein said CD71-positive cells are myeloid precursor cells.

Claim 59. (withdrawn) The method of claim 53 wherein said cells are selected from the group consisting of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

Claim 60. (original) A composition comprising recombinant human uteroglobin and fibronectin, each present in an amount sufficient to suppress proliferation of CD71 positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 61. (currently amended) The composition of claim 60 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 62. (withdrawn) A method of suppressing activation of CD71-positive cells in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to suppress activation of said cells.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 63. (withdrawn) The method of claim 62 wherein said patient is diagnosed with an inflammatory disease.

Claim 64. (withdrawn) The method of claim 62 wherein said patient is diagnosed with an infectious disease.

Claim 65. (withdrawn) The method of claim 62 wherein said patient is diagnosed with an autoimmune disease.

Claim 66. (withdrawn) The method of claim 62 wherein said patient is diagnosed with cancer.

Claim 67. (withdrawn) The method of claim 62 wherein said patient is diagnosed with a fibrotic disease.

Claim 68. (withdrawn) A method of claim 62 wherein said cells are selected from the group consisting of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

Claim 69. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to suppress activation of CD71 positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 70. (currently amended) The composition of claim 69 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.



In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 71. (withdrawn) A method of suppressing activation of CD71-positive cells in vitro comprising exposing said cells to an amount of recombinant human uteroglobin sufficient to suppress activation of said cells in vitro.

Claim 72. (withdrawn) The method of claim 71 wherein said CD71-positive cells are hematopoietic stem cells.

Claim 73. (withdrawn) The method of claim 72 wherein said hematopoietic stem cells are to be transplanted from a donor to a recipient in need of such cells.

Claim 74. (withdrawn) The method of claim 73 wherein said hematopoietic stem cells are stored for a period of time prior to transplant.

Claim 75. (withdrawn) The method of claim 71 wherein said CD71-positive cells are lymphoid precursor cells.

Claim 76. (withdrawn) The method of claim 71 wherein said CD71-positive cells are myeloid precursor cells.

Claim 77. (withdrawn) The method of claim 71 wherein said cells are selected from the group consisting of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

Claim 78. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to suppress activation of CD71 positive cells in vitro.

Claim 79. (currently amended) The composition of claim 78 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 80. (withdrawn) A method of enhancing proliferation of CD11b-positive cells in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to enhance proliferation of said cells.

Claim 81. (withdrawn) The method of claim 80 wherein said patient is diagnosed with a leukemia.

Claim 82. (withdrawn) The method of claim 80 wherein said patient is diagnosed with a lymphoma.

Claim 83. (withdrawn) The method of claim 80 wherein said patient is diagnosed with an inflammatory disease.

Claim 84. (withdrawn) The method of claim 80 wherein said patient is diagnosed with an infectious disease.

Claim 85. (withdrawn) The method of claim 80 wherein said patient is diagnosed with a fibrotic disease.

Claim 86. (withdrawn) The method of claim 80 wherein said patient is diagnosed with an autoimmune disease.

Claim 87. (withdrawn) The method of claim 80 wherein said patient is diagnosed with cancer.

Claim 88. (withdrawn) The method of claim 80 wherein said cells are selected from the group consisting of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 89. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to enhance proliferation of CD11b-positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 90. (currently amended) The composition of claim 89 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 91. (withdrawn) A method of enhancing proliferation of CD11b-positive cells in vitro comprising exposing said cells to an amount of recombinant human uteroglobin sufficient to enhance proliferation of said cells in vitro.

Claim 92. (withdrawn) The method of claim 91 wherein said CD11b-positive cells are hematopoietic stem cells.

Claim 93. (withdrawn) The method of claim 92 wherein said hematopoietic stem cells are to be transplanted from a donor to a recipient in need of such cells.

Claim 94. (withdrawn) The method of claim 93 wherein said hematopoietic stem cells are stored for a period of time prior to transplant.

Claim 95. (withdrawn) The method of claim 91 wherein said CD11b-positive cells are lymphoid precursor cells.

Claim 96. (withdrawn) The method of claim 91 wherein said CD11b-positive cells are myeloid precursor cells.

Claim 97. (withdrawn) The method of claim 91 wherein said cells are selected from the group consisting of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 98. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to enhance proliferation of CD11b-positive cells in vitro.

Claim 99. (currently amended) The composition of claim 98 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 100. (withdrawn) A method of enhancing activation of CD11b-positive cells in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to enhance activation of said cells.

Claim 101. (withdrawn) The method of claim 100 wherein said patient is diagnosed with an inflammatory disease.

Claim 102. (withdrawn) The method of claim 100 wherein said patient is diagnosed with an infectious disease.

Claim 103. (withdrawn) The method of claim 100 wherein said patient is diagnosed with an autoimmune disease.

Claim 104. (withdrawn) The method of claim 100 wherein said patient is diagnosed with cancer.

Claim 105. (withdrawn) The method of claim 100 wherein said patient is diagnosed with a fibrotic disease.

Claim 106. (withdrawn) A method of claim 100 wherein said cells are selected from the group consisting of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 107. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to enhance activation of CD11b-positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 108. (currently amended) The composition of claim 107 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 109. (withdrawn) A method of enhancing activation of CD11b-positive cells in vitro comprising exposing said cells to an amount of recombinant human uteroglobin sufficient to enhance activation of said cells in vitro.

Claim 110. (withdrawn) The method of claim 109 wherein said CD11b-positive cells are hematopoietic stem cells.

Claim 111. (withdrawn) The method of claim 110 wherein said hematopoietic stem cells are to be transplanted from a donor to a recipient in need of such cells.

Claim 112. (withdrawn) The method of claim 111 wherein said hematopoietic stem cells are stored for a period of time prior to transplant.

Claim 113. (withdrawn) The method of claim 109 wherein said CD71-positive cells are lymphoid precursor cells.

Claim 114. (withdrawn) The method of claim 109 wherein said CD71-positive cells are myeloid precursor cells.

Claim 115. (withdrawn) The method of claim 109 wherein said cells are selected from The group consistin of: neutrophils, band cells, stab cells, granulocytes, eosinophils, basophils, monocytes, macrophages, lymphocytes, erythrocytes, megakaryocytes, T cells, B cells, NK cells, lymphoid precursors, and myeloid precursors.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 116. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to enhance activation of CD11b-positive cells in vitro.

Claim 117. (currently amended) The composition of claim 116 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 118. (withdrawn) A method of inhibiting migration of vascular endothelial cells comprising administering recombinant human uteroglobin to a patient in need of such treatment in an amount sufficient to inhibit migration of said cells.

Claim 119. (withdrawn) The method of claim 118 wherein said patient has been diagnosed with a primary cancer.

Claim 120. (withdrawn) The method of claim 119 wherein the recombinant human uteroglobin inhibits or prevents metastasis of the primary cancer.

Claim 121. (withdrawn) The method of 118 wherein said patient has been diagnosed with a diabetic condition.

Claim 122. (withdrawn) The method of 118 wherein the recombinant human uteroglobin inhibits or prevents retinopathy.

Claim 123. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to suppress migration of vascular endothelial cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 124. (currently amended) The composition of claim 123 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 125. (withdrawn) A method of inhibiting angiogenesis in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to inhibit angiogenesis.

Claim 126. (original) A composition comprising recombinant human uteroglobin in an amount sufficient to inhibit angiogenesis in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 127. (currently amended) The composition of claim 126 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 128. (withdrawn) A method of inhibiting migration of vascular endothelial cells in a patient in need of such treatment comprising administering to said patient recombinant human uteroglobin and fibronectin or a fragment derived from fibronectin in amounts sufficient to inhibit migration of said cells.

Claim 129. (original) A composition comprising recombinant human uteroglobin and fibronectin, or a fragment derived from fibronectin, in amounts sufficient to suppress migration of vascular endothelial cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 130. (currently amended) The composition of claim 129 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 131. (withdrawn) A method of inhibiting angiogenesis in a patient in need of such treatment comprising administering to said patient recombinant human uteroglobin and fibronectin, or a fragment derived from fibronectin, in amounts sufficient to inhibit angiogenesis.

Claim 132. (original) A composition comprising recombinant human uteroglobin and fibronectin or a fragment derived from fibronectin in amounts sufficient to inhibit angiogenesis in a patient, and a pharmaceutically acceptable carrier or diluent.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 133. (currently amended) The composition of claim 132 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 134. (withdrawn) A method of inhibiting extracellular matrix invasion by vascular endothelial cells in a patient in need of such treatment comprising administering to said patient an amount of recombinant human uteroglobin sufficient to inhibit extracellular matrix invasion of said cells.

Claim 135. (currently amended) A composition comprising recombinant human uteroglobin in an amount sufficient to inhibit extracellular matrix invasion by vascular endothelial cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 136. (currently amended) The composition of claim 135 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 137. (withdrawn) A method of inhibiting extracellular matrix invasion by vascular endothelial cells in a patient in need of such treatment comprising administering to said patient recombinant human uteroglobin and fibronectin or a fragment derived from fibronectin in amounts sufficient to inhibit extracellular matrix invasion.

Claim 138. (original) A composition comprising recombinant human uteroglobin and fibronectin or a fragment derived from fibronectin in amounts sufficient to inhibit extracellular matrix invasion by vascular endothelial cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 139. (currently amended) The composition of claim 138 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.



In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 140. (withdrawn) A method of regulating signal transduction in uteroglobin-responsive cells said method comprising exposing said cells to recombinant human uteroglobin, wherein said signal transduction is mediated by CD148 and CD148 immunoreactive proteins.

Claim 141. (withdrawn) The method of claim 140 further comprising exposing said cells to fibronectin or a fibronectin immunoreactive protein.

Claim 142. (withdrawn) The method of claim 140 wherein arachidonic acid metabolism is regulated.

Claim 143. (withdrawn) The method of claim 140 wherein nitric oxide metabolism is regulated.

Claim 144. (withdrawn) The method of claim 140 wherein the cell cycle is regulated.

Claim 145. (withdrawn) The method of claim 140 wherein cell adhesion molecule and/or integrin expression is regulated.

Claim 146. (withdrawn) A method of regulating cellular activities mediated by CD148 and CD148 immunoreactive proteins comprising exposing the cells to recombinant human uteroglobin.

Claim 147. (withdrawn) The method of claim 146 further comprising exposing said cells to fibronectin or a fibronectin immunoreactive protein.

Claim 148. (withdrawn) The method of claim 146 wherein cellular adhesion is regulated.

Claim 149. (withdrawn) The method of claim 146 wherein cellular metabolism is regulated.

Claim 150. (withdrawn) The method of claim 146 wherein cellular migration is regulated.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 151. (withdrawn) The method of claim 146 wherein cellular proliferation is regulated.

Claim 152. (withdrawn) The method of claim 146 wherein cellular extracellular matrix invasion is regulated.

Claim 153. (withdrawn) The method of claim 146 wherein angiogenesis is regulated.

Claim 154. (withdrawn) The method of claim 146 wherein cellular differentiation is regulated.

Claim 155. (withdrawn) A method of regulating signal transduction in uteroglobin-responsive cells said method comprising exposing said cells to recombinant human uteroglobin, wherein said signal transduction is mediated by PLA2 receptors and PLA2 immunoreactive proteins.

Claim 156. (withdrawn) The method of claim 155 further comprising exposing said cells to fibronectin or a fibronectin immunoreactive protein.

Claim 157. (withdrawn) The method of claim 155 wherein arachidonic acid metabolism is regulated.

Claim 158. (withdrawn) The method of claim 155 wherein nitric oxide metabolism is regulated.

Claim 159. (withdrawn) The method of claim 155 wherein the cell cycle is regulated.

Claim 160. (withdrawn) The method of claim 155 wherein cell adhesion molecule and/or integrin expression is regulated.

Claim 161. (withdrawn) A method of regulating cellular activities mediated by CD148 and CD148 immunoreactive proteins comprising exposing the cells to recombinant human uteroglobin.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 162. (withdrawn) The method of claim 161 further comprising exposing said cells to fibronectin or a fibronectin immunoreactive protein.

Claim 163. (withdrawn) The method of claim 161 wherein cellular adhesion is regulated.

Claim 164. (withdrawn) The method of claim 161 wherein cellular metabolism is regulated.

Claim 165. (withdrawn) The method of claim 161 wherein cellular migration is regulated.

Claim 166. (withdrawn) The method of claim 161 wherein cellular proliferation is regulated.

Claim 167. (withdrawn) The method of claim 161 wherein cellular extracellular matrix invasion is regulated.

Claim 168. (withdrawn) The method of claim 161 wherein angiogenesis is regulated.

Claim 169. (withdrawn) The method of claim 161 wherein cellular differentiation is regulated.

Claim 170. (withdrawn) A method of identifying proteins that interact with each other, in which at least one protein contains at least one four helical bundle motif and at least one protein having at least one fibronectin Type III domain comprising mapping a pathway involving one or more protein interactions.

Claim 171. (withdrawn) The method of claim 170 wherein the pathway is physiological.

Claim 172. (withdrawn) The method of claim 170 wherein the pathway is pathological.

Claim 173. (withdrawn) The method of claim 170 wherein the pathway is pharmacological.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 174. (withdrawn) The method of claim 170 wherein receptors for rhUG and UG-like proteins are identified.

Claim 175. (withdrawn) The method of claim 170 wherein receptors for fibronectin and fibronectin immunoreactive proteins are identified.

Claim 176. (withdrawn) The method of claim 170 wherein receptors for proteins containing a four helical bundle motif are identified.

Claim 177. (withdrawn) The method of claim 170 wherein receptors for proteins containing a fibronectin Type III domain are identified.

Claim 178. (withdrawn) The method of claim 170 wherein ligands for proteins containing a four helical bundle motif are identified.

Claim 179. (withdrawn) The method of claim 170 wherein ligands for proteins containing a fibronectin Type III domain are identified.

Claim 180. (withdrawn) The method of claim 170 wherein ligands for CD148 and CD148 immunoreactive proteins are identified.

Claim 181. (withdrawn) The method of claim 170 wherein proteins with which rhUG and rhUG-like proteins can form a complex are identified.

Claim 182. (withdrawn) The method of claim 170 wherein proteins with which fibronectin and fibronectin immunoreactive proteins can form a complex are identified.

Claim 183. (withdrawn) The method of claim 170 wherein proteins bearing fibronectin Type III repeats are identified, wherein said proteins are selected from the group consisting of:

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

fibronectin, CD148, collagens, titins, tenascins, cytotactins, fibrin, cell adhesion molecules, integrins, protein tyrosine phosphatases, and others.

Claim 184. (withdrawn) The method of claim 170 wherein proteins bearing four helical bundle motifs are identified, wherein said proteins are selected from the group consisting of: UG-like proteins, the secretory PLA2 protein family (including all subtypes), the annexins, and others.

Claim 185. (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to inhibit LPS-dependent inflammatory processes in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 186. (new) The composition of claim 185 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 187. (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to decrease TNF-alpha concentrations and a pharmaceutically acceptable carrier or diluent.

Claim 188. (new) The composition of claim 187 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 189. (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to regulate the nitric oxide pathway of a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 190. (new) The composition of claim 189 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 191. (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to regulate vascular permeability of a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 192. (new) The composition of claim 191 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 193. (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to suppress proliferation of CD71 positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 194 (new) The composition of claim 193 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 195 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to suppress proliferation of CD71 positive cells in vitro.

Claim 196 (new) The composition of claim 195 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 197 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1, and fibronectin, each present in an amount sufficient to suppress proliferation of CD71 positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 198 (new) The composition of claim 197 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 199 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to suppress activation of CD71 positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 200 (new) The composition of claim 199 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 201 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to suppress activation of CD71 positive cells in vitro.

Claim 202 (new) The composition of claim 201 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 203 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to enhance proliferation of CD11b-positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 204 (new) The composition of claim 203 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 205 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to enhance proliferation of CD11b-positive cells in vitro.

Claim 206 (new) The composition of claim 205 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

Claim 207 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to enhance activation of CD11b-positive cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 208 (new) The composition of claim 207 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 209 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to enhance activation of CD11b-positive cells in vitro.

Claim 210 (new) The composition of claim 209 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 211 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to suppress migration of vascular endothelial cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 212 (new) The composition of claim 211 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 213 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to inhibit angiogenesis in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 214 (new) The composition of claim 213 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 215 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1, and fibronectin, or a fragment derived from fibronectin, in amounts



In re Application of: Pilon, Aprile et al.  
Serial No.: 09/835,784  
Filed: April 13, 2001

sufficient to suppress migration of vascular endothelial cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 216 (new) The composition of claim 215 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 217 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1, and fibronectin or a fragment derived from fibronectin, in amounts sufficient to inhibit angiogenesis in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 218 (new) The composition of claim 217 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 219 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1 in an amount sufficient to inhibit extracellular matrix invasion by vascular endothelial cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 220 (new) The composition of claim 219 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.

Claim 221 (new) A composition comprising recombinant human uteroglobin consisting essentially of SEQ ID NO. 1, and fibronectin or a fragment derived from fibronectin in amounts sufficient to inhibit extracellular matrix invasion by vascular endothelial cells in a patient, and a pharmaceutically acceptable carrier or diluent.

Claim 222. (new) The composition of claim 221 wherein said amount of recombinant human uteroglobin is 10 ng/kg - 25 mg/kg of body mass.